Humacyte adds Scott Coward and Paul Kuznik to board of directors

Humacyte, Inc. (Nasdaq: HUMA) announced on September 28, 2026 that its board of directors had appointed Scott Coward and Paul Kuznik, effective September 22, 2026. The Board of Directors appointed Scott Coward and Paul Kuznik to the Board on that date.¹ Coward will serve as a Class I director with a term expiring in 2028, while Kuznik will serve as a Class II director with a term expiring in 2029, in each case subject to earlier death, resignation, retirement, disqualification, or removal.¹

Coward has spent his career in legal and executive roles at life sciences companies. He has worked as an attorney at K&L Gates since July 2026 after previously spending years there as managing partner of the Raleigh office, and before that he held the roles of executive vice president, chief legal officer, chief administrative officer, and secretary at Exact Sciences Corporation between January 2015 and December 2022.¹ He led the integration of Genomic Health Corporation after its acquisition by Exact Sciences and later served on the Exact Sciences board from December 2022 to March 2026.¹ He has been named to Humacyte's Audit Committee, according to the filing.

Kuznik brings decades of vascular and cardiovascular device experience. From 2015 to 2018 he served as chief executive officer and a board member of Bolton Medical, a developer of endovascular technologies for complex aortic disease that was acquired by Terumo Corporation.¹ He then helped integrate Bolton Medical with Vascutek to form Terumo Aortic, serving as its U.S. president from 2019 to 2020 and North America president from 2020 to 2023.¹ He has joined Humacyte's Commercial Committee.

Each director will receive a $50,000 annual cash retainer, $5,000 per year for committee service, and an option to purchase 125,000 shares of Humacyte common stock, prorated for 2026.¹ The filing states there is no arrangement tying either appointment to another party and that neither director has a material interest requiring disclosure under Item 404(a) of Regulation S-K.¹